Mission Bio highlighted advancements in single-cell multiomics at the 66th ASH Annual Meeting and Exposition, showcasing how its Tapestri Platform is driving breakthroughs in hematological cancer research and therapy development. The presentations spanned multiple myeloma (MM), acute myeloid leukemia (AML), lymphoma, and CAR-T therapy, demonstrating the platform's ability to provide a deeper understanding of disease mechanisms and therapeutic responses.
Single-Cell Multiomics in Multiple Myeloma
Mission Bio presented new datasets for its Tapestri Single-cell Multiple Myeloma Multiomics Solution, commercially available this year. The data integrates genomic, immunophenotypic, and clonotypic assessment to pinpoint disease-driving clones in MM. Adam Sciambi, CTO and co-founder of Mission Bio, stated, "Our ongoing mission is to provide scientists with the means to understand hard-to-treat diseases like MM in ways that will lead to new, more effective treatments."
The research highlighted the role of rare clones in the progression from precursor conditions like monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) to full-blown MM, as well as the comprehensive clonal architecture underlying relapse and treatment resistance.
Refining MRD Assessment in Acute Myeloid Leukemia
A study from Heidelberg University Hospital demonstrated the value of single-cell DNA+protein multiomics sequencing to refine minimal residual disease (MRD) assessment in AML. The research, titled "Clonal Dynamics of Leukemic and Clonal Hematopoiesis Mutations Predict Relapse in Single Cell MRD Analysis of AML in First Complete Remission," used patient samples to show how this approach offers greater precision than current techniques, potentially redefining AML MRD.
Single-Cell DNA and Fusion Profiling in Pediatric Leukemia
Researchers from the University of Cincinnati introduced data demonstrating the feasibility of integrating DNA and fusion profiling at the single-cell level as a multiomic approach for pediatric leukemia. The presentation, titled "Single-Cell Multi-Omic Analysis of KMT2A-Rearranged Pediatric Acute Leukemia Clonal Evolution," is the first to combine simultaneous molecular profiling and fusion identification at the single-cell level for pediatric leukemia.
Genomic Insights in CAR-T Therapy
Following a recent publication in the New England Journal of Medicine, new findings from Stanford University highlighted the power of single-cell DNA sequencing to uncover critical genomic insights in chimeric antigen receptor (CAR) T-cell therapy. The research revealed myeloid predominance for TP53 clonal hematopoiesis in post-CAR therapy myeloid neoplasms (tMN) among non-Hodgkin lymphoma patients. These findings, presented under the title "Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms," underscore the potential of single-cell DNA sequencing to inform CAR T therapy development, enabling safer treatments by addressing risks tied to therapy-induced molecular changes.
